Last reviewed · How we verify

NCT03639428: MIDAZOLAM

Pharmacokinetic Evaluation of MDZ028

Completed Last updated 21 August 2018
What this trial tests

trial testing Midazolam in Midazolam in 37 participants. Completed in 30 November 2017.

Timeline
23 June 2011
Primary endpoint
30 November 2017
30 November 2017

Quick facts

Lead sponsorCentre Hospitalier Universitaire, Amiens
StatusCompleted
Study typeOBSERVATIONAL
Enrollment37
Start date23 June 2011
Primary completion30 November 2017
Estimated completion30 November 2017

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire, Amiens

Who can join

Adults 6 Months to 18, any sex, with Midazolam. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Plasma concentration data were collected from 37 paedriatic patients and 12 healthy adults recruited in a single dose, open-label phase II pharmacokinetic study and in a single dose, randomised, open-label two-peiod crossover bioavailability study, respectively. Data were analysed using non-linear mixed effect modeling.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Midazolam

Trials testing the same drug.

Other recruiting trials for Midazolam

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire, Amiens trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03639428.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing